Prinston Inc Generic Rivaroxaban Receives Tentative Approval in US
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
J&J, Bristol Myers lose challenges to US drug price negotiation program
Bayer`s patent for blood thinner Xarelto invalid, UK court rules
Tiefenbacher Pharmaceuticals successfully prepares the launch of the anticoagulant Rivaroxaban.
Ami Have Received Cep Approval For Rivaroxaban,Used An Anti-Coagulating Agent
NEW BRUNSWICK, N.J., April 8, 2024 /PRNewswire/ -- Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® (rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.1,2 These data were featured in an oral presentation yesterday at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta, Georgia (Abstract #906-04).
Breckenridge Pharma`s Generic Rivaroxaban Receives Approval in the U.S.
Viatris` Rivaroxaban Receives Approval in Europe
Tiefenbacher Launch anticoagulant Rivaroxaban in Canada